Ardelyx gains after marketing deal with LPGA
Source: SeekingAlpha
2026-02-24 09:58:05 ET
More on Ardelyx
- Why Ardelyx's Offensive Strategy Doesn't Move The Needle
- Ardelyx, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability
- Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook
- Ardelyx outlines $1B IBSRELA revenue target by 2029 while advancing CIC label expansion and new pipeline
Read the full article on Seeking Alpha
For further details see:
Ardelyx gains after insider purchase, LPGA marketing deal
Ardelyx Inc.
NASDAQ: ARDX
ARDX Trading
2.1% G/L:
$5.83 Last:
1,179,729 Volume:
$5.70 Open:
ARDX Latest News
March 12, 2026 08:00:00 am
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
ARDX Stock Data
$1,798,009,864
231,311,539
0.67%
75
N/A
Biotechnology & Life Sciences
Healthcare
US
WALTHAM
